Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts.

Autor:	Nachbagauer R; 1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY USA., Salaun B; 2GSK, Rixensart, Belgium., Stadlbauer D; 1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY USA., Behzadi MA; 1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY USA., Friel D; 3GSK, Wavre, Belgium., Rajabhathor A; 1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY USA., Choi A; 1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY USA.; 4Graduate School of Biomedical Services, Icahn School of Medicine at Mount Sinai, New York, NY USA., Albrecht RA; 1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY USA.; 5Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY USA., Debois M; 3GSK, Wavre, Belgium., García-Sastre A; 1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY USA.; 5Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY USA.; 6Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY USA., Rouxel RN; 2GSK, Rixensart, Belgium., Sun W; 1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY USA., Palese P; 1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY USA.; 6Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY USA., Mallett CP; 7GSK, Rockville, MD 20850 USA., Innis BL; 8GSK, King of Prussia, PA USA.; 10Present Address: PATH, Washington, DC, USA., Krammer F; 1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY USA., Claeys C; 9GSK, Rixensart, Belgium.; Present Address: Spmt-Arista Asbl, Brussel, Belgium.
Jazyk:	angličtina
Zdroj:	NPJ vaccines [NPJ Vaccines] 2019 Dec 06; Vol. 4, pp. 51. Date of Electronic Publication: 2019 Dec 06 (Print Publication: 2019).
DOI:	10.1038/s41541-019-0147-z
Abstrakt:	Licensed influenza virus vaccines target the head domain of the hemagglutinin (HA) glycoprotein which undergoes constant antigenic drift. The highly conserved HA stalk domain is an attractive target to increase immunologic breadth required for universal influenza virus vaccines. We tested the hypothesis that immunization with a pandemic influenza virus vaccine boosts pre-existing anti-stalk antibodies. We used chimeric cH6/1, full length H2 and H18 HA antigens in an ELISA to measure anti-stalk antibodies in recipients participating in clinical trials of A/H1N1, A/H5N1 and A/H9N2 vaccines. The vaccines induced high titers of anti-H1 stalk antibodies in adults and children, with higher titers elicited by AS03-adjuvanted vaccines. We also observed cross-reactivity to H2 and H18 HAs. The A/H9N2 vaccine elicited plasmablast and memory B-cell responses. Post-vaccination serum from vaccinees protected mice against lethal challenge with cH6/1N5 and cH5/3N4 viruses. These findings support the concept of a chimeric HA stalk-based universal influenza virus vaccine. clinicaltrials.gov: NCT02415842. Competing Interests: Competing interestsF.K., A.G.-S., and P.P. report study funding from the GSK group of companies. R.N., A.G.-S., P.P., F.K., C.P.M., and B.L.I. are named as inventor on a patent family regarding influenza virus vaccine constructs filed by the Icahn School of Medicine at Mount Sinai and the GSK group of companies. A.G.-S. also reports he is an inventor of a Mount Sinai owned patent on plasmid-based rescue technologies to generate recombinant influenza viruses with royalties paid to Medimmune. R.A.A. reports grants from National Institutes of Health, outside the submitted work. B.S., D.F., M.D., R.N.R., and C.P.M. are employed by the GSK group of companies. B.S., M.D., C.P.M., and C.C. hold shares in the GSK group of companies. C.C. and B.L.I. were employed by the GSK group of companies at the time of the study. D.S., M.A.B., A.C., W.S., and A.R. have nothing to disclose. (© The Author(s) 2019.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu